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Abstract
Background:  The efficacy of natural products (NPs) is being evaluated using randomized
controlled trials (RCTs) with increasing frequency, yet a search of the literature did not identify a
widely accepted critical appraisal instrument developed specifically for use with NPs. The purpose
of this project was to develop and evaluate a critical appraisal instrument that is sufficiently rigorous
to be used in evaluating RCTs of conventional medicines, and also has a section specific for use with
single entity NPs, including herbs and natural sourced chemicals.
Methods: Three phases of the project included: 1) using experts and a Delphi process to reach
consensus on a list of items essential in describing the identity of an NP; 2) compiling a list of non-
NP items important for evaluating the quality of an RCT using systematic review methodology to
identify published instruments and then compiling item categories that were part of a validated
instrument and/or had empirical evidence to support their inclusion and 3) conducting a field test
to compare the new instrument to a published instrument for usefulness in evaluating the quality
of 3 RCTs of a NP and in applying results to practice.
Results: Two Delphi rounds resulted in a list of 15 items essential in describing NPs. Seventeen
item categories fitting inclusion criteria were identified from published instruments for
conventional medicines. The new assessment instrument was assembled based on content of the
two lists and the addition of a Reviewer's Conclusion section. The field test of the new instrument
showed good criterion validity. Participants found it useful in translating evidence from RCTs to
practice.
Conclusion: A new instrument for the critical appraisal of RCTs of NPs was developed and tested.
The instrument is distinct from other available assessment instruments for RCTs of NPs in its
systematic development and validation. The instrument is ready to be used by pharmacy students,
health care practitioners and academics and will continue to be refined as required.
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Background
The use of Complementary and Alternative Medicine
(CAM) has steadily increased in North America in the last
2 decades. Coinciding with the increase in use, the scien-
tific evaluation of the efficacy and safety of CAM practices
and products is also on the rise. In fact, a recent editorial
reported that in 2008 more than 7500 CAM trials were
indexed in MEDLINE [1].
The evaluation of the efficacy of CAM practices and prod-
ucts using the same methodology used for conventional
practices and products is controversial. It can be argued
that a randomized controlled trial (RCT), considered to be
gold standard methodology in evaluating conventional
medicine, may not adequately approximate how the CAM
is used in practice and therefore may not be a fair way to
assess efficacy. Of all the practices and products that make
up CAM, natural products (NPs), including herbal medi-
cines and natural sourced chemicals, most closely resem-
ble conventional medications in terms of method of
administration and the ability to quantify the adminis-
tered dose. Like conventional medications, NPs are, there-
fore, well suited to evaluation using RCTs.
Health care professionals are accustomed to using evi-
dence based information regarding the efficacy of conven-
tional medicines as one part of their clinical decision
making and therefore prefer to use evidence based infor-
mation when helping patients make decisions about the
use of CAM such as NPs. RCTs, conducted to determine
efficacy of NPs, are being performed and published with
increasing frequency. However, the critical appraisal of
these trials, necessary to establish evidence based informa-
tion, is more complex than with conventional medica-
tions due to the potential for variation in chemical
content of NPs. RCTs completed using the best methodol-
ogy do not reliably assess efficacy if the content of the NP
being evaluated is not known or reported. The importance
of the content of the NP and its potential for variation in
content and thus activity is often not recognized or is
underestimated. [1] This leads to difficulty in applying the
results of RCTs of NPs to a patient's question about the
utility of a particular NP.
The need to be able to assess the quality of RCTs of NPs
prompted us to search the literature to identify an instru-
ment to use in critically appraising RCTs of NPs. Our sys-
tematic review identified 16 published instruments for
evaluating the quality of RCTs of NPs, however, none of
the instruments stated that they had been validated and
there did not appear to be a widely accepted gold standard
instrument [2]. The CONSORT Statement for Herbal
Interventions [3] came closest to fulfilling requirements
for a quality instrument to critically appraise RCTs of NPs,
however its content is specific for use with herbal medi-
cines. There is therefore a need to develop an instrument
that will have a broader use in critically assessing the qual-
ity of RCTs of NPs that include herbs as well as single, nat-
ural sourced chemicals. Initially we proposed identifying
a critical appraisal instrument that was designed for eval-
uating RCTs of conventional medicines and then adding a
section specific for NPs. We subsequently determined that
although there are many instruments available, there did
not appear to be agreement as to which instrument was
the "gold standard".
The purpose of this project was to develop and evaluate a
critical appraisal instrument that is sufficiently rigorous to
be used in evaluating RCTs of conventional medicines,
and also has a section specific for use with single entity
NPs, including herbs and natural sourced chemicals.
Methods
The development and evaluation of a critical appraisal
instrument for evaluating RCTs of NPs was divided into 3
distinct phases: establishment of a list of items essential in
describing the identify of an NP, establishment of a list of
non-NP items important for evaluating the quality of an
RCT and, finally, a pilot study to compare the new instru-
ment to a published instrument for usefulness in evaluat-
ing the quality of RCTs of NPs and in helping to answer a
clinical question.
Phase 1. Establishment of a list of items essential in 
describing the identity of an NP
Selection of items
the initial list of items for this study was compiled from
items contained in published critical appraisal instru-
ments designed for RCTs of NPs as well as from items sug-
gested by the research team.
Participants
A list of 14 potential participants from disciplines includ-
ing: natural products chemistry/pharmacognosy (n = 6),
botany (n = 1), ethnobotany (n = 2), pharmacology of
natural products (n = 1) and critical appraisal (n = 4) was
compiled. Each participant was assigned a unique code
(known only to the research assistant) and was sent an
individual recruitment letter via e-mail. In anticipation of
willingness to participate, potential participants were also
sent the initial list of NP items along with instructions for
completion
Procedure
the Delphi process [4] was used to achieve consensus
among a group of experts as to which items describing the
identity of an NP were essential to consider when critically
appraising an RCT of an NP. The consensus building proc-
ess was conducted in 2 rounds using email. All email con-
tact with participants was conducted through individual
emails (not one email containing all 14 addresses) to
maintain anonymity. The research assistant was responsi-BMC Complementary and Alternative Medicine 2009, 9:11 http://www.biomedcentral.com/1472-6882/9/11
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ble for receiving and collating all results, using partici-
pants' codes. All collated results viewed by participants
had names and codes removed to maintain anonymity.
Consensus was considered to have been reached when
80% of participants were in agreement with an item being
designated as essential to include in the instrument.
Delphi Consensus-Round 1
participants who agreed to participate were instructed to
review the list of NP items on the Round 1 study form and
indicate, using "yes, no, or uncertain", whether they felt
that each item was essential to include in an assessment
instrument used to evaluate RCTs of NPs. Participants
were encouraged to submit comments regarding the
wording of items and suggestions for additional items
they felt should be included. Round 1 study forms were to
be completed and returned by e-mail within two weeks of
receipt. A reminder e-mail was sent to participants who
did not respond to the initial email request for participa-
tion or had agreed to participate and had not returned the
completed Round 1 form.
Delphi Consensus-Round 2
Round 2 study forms were created by compiling all
responses, comments and suggestions for addition, with
all identifiers removed. Follow-up letters and Round 2
study forms were sent to each participant via individual e-
mail. Participants were instructed to comment on the
revised list of items as well as on any comments or sugges-
tions recorded from Round 1. A reminder e-mail was sent
to each participant who did not respond within 14 days.
Analysis
Round 1: Responses, comments and suggestions from all
completed Round 1 study forms were recorded and
reviewed, using participants' codes to maintain confiden-
tiality. A revised list of items was compiled based on par-
ticipants' feedback and investigator expertise and was
used for Round 2. Round 2: Responses and comments on
all completed Round 2 forms were recorded and analyzed
and a final list of items considered to be essential by the
study participants and investigators was assembled
Phase 2. Establishment of list of important non-NP items
Identification of critical appraisal instruments for RCTs of 
conventional medications and NPs
A systematic review of the literature was conducted to
identify critical appraisal instruments of RCTs of conven-
tional medications and NPs, with the purpose of identify-
ing items used in published instruments. Details from the
portion of the systematic review pertaining to instruments
designed for NPs were published previously [2]. Data-
bases (PubMed, Embase, Web of Science, CINAHL, IPA
and Cochrane Library) were searched from inception to
June 2006 to identify potentially relevant articles that
described the critical appraisal of RCTs of conventional
medications. Search terms were: critical appraisal, scale,
checklist, instrument, randomized controlled trial, sys-
tematic review, meta analysis, tool, form, evidence based
medicine, quality control, quality assessment and stand-
ards. Searches were limited to articles written in English.
Evidence-based medicine websites, textbooks and investi-
gators files were searched for additional instruments. Bib-
liographies of relevant references were reviewed to
identify additional articles.
Full articles of potentially relevant citations were retrieved
and evaluated for relevance by two investigators, with dis-
agreements being resolved by a third investigator. Articles
were deemed relevant if they contained an instrument
used for the assessment of RCTs of conventional medi-
cine, described how to report an RCT of conventional
medicine or discussed the importance of quality assess-
ment and provided suggested items essential to the assess-
ment. Articles were excluded if they contained an
instrument that had been previously published, con-
tained an instrument designed specifically for the assess-
ment of a meta-analysis, a systematic review or for a trial
design other than RCT or contained an instrument
designed for the assessment of RCTs of therapies other
than medication.
Compilation of items from critical appraisal instruments for 
conventional medications
a list of all items contained in assessment instruments for
conventional medications and guidance documents was
compiled, using a process similar to that used for the NP
instruments [2]. A table, using the Revised CONSORT
statement [5] as a framework, was used to record all items.
Items contained in assessment instruments, but not found
in the Revised CONSORT statement, were recorded in a
separate section labeled as miscellaneous items. Items
from instruments that were reported to have been vali-
dated and/or there was empirical evidence provided for
the importance of including the items were noted.
Analysis
The list of all items from conventional instruments was
examined for items essential for inclusion in the new crit-
ical appraisal instrument. To be designated as essential to
include in the new critical appraisal instrument, an item
had to meet at least 1 of the following 2 inclusion criteria:
it had to have been contained in a published instrument
that was documented as having been validated or must
have had empirical evidence to support its inclusion in a
published instrument. Originally we planned to have a
third criterion, which was that the item had to have been
included in the more than 50% of critical appraisal instru-
ments. This criterion was removed from consideration for
reasons that are provided in the Discussion section.BMC Complementary and Alternative Medicine 2009, 9:11 http://www.biomedcentral.com/1472-6882/9/11
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Phase 3. Field test of new assessment instrument
Purpose
to evaluate the new assessment instrument by 1) compar-
ing the performance of the new assessment instrument to
that of a published assessment instrument in evaluating
the quality of RCTs of NPs and helping to answer a clinical
question; 2) measuring the validity of each criterion; 3)
determining the potential impact of the order of use of the
instruments.
Study design
the randomized trial was approved by the Dalhousie Uni-
versity Health Sciences and Humanities Human Research
Ethics Board, with participants and primary researchers
(TJ and AMW) being blinded as to which group the partic-
ipants were assigned. To be eligible to take part in the
study, participants had to fit one of the following inclu-
sion criteria: be a practicing pharmacist, be a student cur-
rently enrolled in a pharmacy program or be an academic
involved in the teaching of critical appraisal skills or clin-
ical skills to pharmacy students. People were excluded
from participating if they had been involved in any of the
earlier phases of development of the new instrument. A
sample size of 14 was determined to be sufficient, based
on a similar study [6]. Participants were given 3 weeks to
complete the study and return all materials. They received
a reminder after 3 weeks if the completed material was not
received by the research assistant and provided additional
time, if required to complete the assessment.
Materials
Three published RCTs evaluating the efficacy of soy isofla-
vones in treating hot flashes were selected, based on having
a range of quality of trials for the study. All identifiers, includ-
ing authors, affiliations and journal citation were removed
from the 3 articles. A clinical case describing a woman expe-
riencing hot flashes as a consequence of menopause, was
prepared. Participants were asked to apply the results of the
RCT to the case by answering the following clinical question:
"In a 53-year-old postmenopausal woman experiencing 5 –
10 hot flashes per day would soy isoflavone extract decrease
the frequency and severity of the hot flashes?".
The draft new assessment instrument developed in the
first 2 phases of this project, along with a User's Guide was
provided for the appraisal of each RCT. A published
assessment instrument used for reviewing clinical trials of
herbal products was selected as a comparator instrument
[7]. Permission was obtained from the publisher to use
the assessment instrument. All identifiers were removed
from both instruments to reduce the risk of bias.
Procedure
Participants were randomly assigned to 1 of 2 groups
using a technique to conceal allocation that involved
selecting 1 of 2 colors of paper out of a hat. Study packages
each contained 2 envelopes, one red and one blue. Each
envelope contained the clinical case and question, an
assessment instrument, a User's Guide, 3 RCTs to be criti-
cally assessed and an evaluation form for feedback on the
usefulness of the assessment instrument. All participants
were instructed to open and complete the red envelope
first. Half of the participants received red envelopes con-
taining the new assessment instrument while the red
envelopes received by the second group of participants
contained the comparator instrument. Participants were
told to open and complete the contents of the blue enve-
lope only after completing the contents of the red enve-
lope. After contents of both envelopes were completed,
participants were instructed to fill out an evaluation form
that asked which instrument they found easiest to use,
which one was most helpful identifying strengths and
weaknesses of the study and in answering the clinical
question and which one was most helpful in selecting an
NP comparable to one used in the RCT.
Analysis
all responses submitted for each item contained in the new
critical appraisal instrument for each of the 3 articles were
recorded by the research assistant (MM), using participants'
codes rather than names to preserve anonymity. To test for
criterion validity, Fisher's exact test was used to compare
responses for each item submitted by each participant to
the investigators "gold standard" answers that were reached
by consensus prior to beginning the trial. Data obtained
from participants' use of the comparator instrument was
analyzed to determine if using the comparator instrument
resulted in the same assignment of overall quality of each
article as was found with the new appraisal instrument.
Fisher's exact test was used to determine if the order in
which the instruments were used affected responses to the
new assessment instrument. Responses to questions on
evaluation sheets were compiled. All comments on the
evaluation sheets, including suggestions for improvement,
were recorded and examined.
Results
Phase 1. Establishment of a list of items essential in 
describing the identity of an NP
Selection of items
Sixteen items describing an NP or its placebo were
selected for inclusion in Round 1 study form (Table 1, col-
umn 1). Thirteen of the 16 items were found in 3 pub-
lished instruments for NPs [3,7,8]. Item #16 (success of
blinding) was included in one instrument and was added
to the initial list [8]. Item #7 (lot number of product) and
item # 15 (description of placebo) were not found in pub-
lished instruments and were added by investigators.
Participants
11 of 14 potential participants completed and returned
the Round 1 study form. Follow-up letters and Round 2BMC Complementary and Alternative Medicine 2009, 9:11 http://www.biomedcentral.com/1472-6882/9/11
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study forms were e-mailed individually to 11 participants.
Eight of 11 participants completed and returned the
Round 2 study form. Specific reasons for not completing
the study were not provided by dropouts.
Delphi Consensus-Round 1
contents of completed study forms were recorded (Table
1). In general, there was a significant amount of agree-
ment with the list of items. In total, participants unani-
mously agreed on the inclusion of 9 of 16 items. The
remaining 7 items each had 1 or 2 participants who either
were uncertain or did not agree that the item was essential
to include in the list. Participants offered suggestions for
clarification of wording of some items. Several partici-
pants suggested the inclusion of additional items that they
felt were missing from the list, such as the stability of the
NP, whether the NP was prepared according to mono-
graph specifications, if a certificate of analysis was pro-
vided, where and when the plant was harvested and
details of the growing conditions.
Delphi Consensus-Round 2
the Round 2 form was created based on review of Round 1
results. There was at least 80% agreement on all items
included on the Round 2 form. Thus these 15 items were
considered by experts and investigators as essential. Twelve
of the 15 items that pertained specifically to the description
of the NP were grouped together (a-h) (Figure 1). Two
Table 1: Results of Delphi Consensus-Round 1
Item Compiled 
Responses
Participant 
Comments
Yes No Un
certain
1. The genus of the test NP was stated. 9 - 2 • Items 1 & 2 assume an organism is used, but there are 
many chemical NPs, so we need to include an unambiguous 
name if it is a natural chemical e.g. arginine is ambiguous, L-
arginine is correct.
2. The species of the test NP was stated. 9 - 1 ￿ Need to be more specific by listing cultivars/varieties
3. The plant part used to prepare the test NP was stated. 10 - 1 ￿ Also when and where harvested
4. How the test NP was processed/extracted was described. 9 1 - ￿ Chemistry and manufacturing information is required by 
the NP Regulations
￿ Proprietary data but for government registration should 
be included but should not be reported in the publication
5. If test NP was a commercial product, brand name was stated. 8 1 1 ￿ Interesting, but not essential.
￿ Brand is important because of differences in 
manufacturing.
6. If test NP was a commercial product, the name of the 
manufacturer was stated.
91 -
7. If test NP was a commercial product, the lot number was 
stated.
8 2 - ￿ Make sure they have enough supply for the complete trial 
and didn't use different lots throughout study
8. The name of important chemical(s)of the test NP was stated. 11 - - ￿ The term "important chemicals" is vague
￿ Full characterization or fingerprinting of the testing 
material
￿ This could be a problem with some products as active 
agent(s) may not be known
￿ Should have a percentage of the chemicals present listed
￿ If standardized for the chemical content and the 
manufacturer wants to be public
9. The amount of important chemical(s) of the test NP was 
stated.
11 - - ￿ The term "important chemicals" is vague
￿ If the makers are not active compounds, there is no need 
to quantify each compound but it is always good to have 
some quantitative information
10. The test NP was analyzed for chemical content. 11 - - ￿ For registration with to government yes but should be 
agreed upon by investigator and company before 
publication.
11. The dosage form of the test NP was stated. 10 - -
12. The dose of the test NP was stated. 10 - -
13. The frequency of administration of the test NP was stated. 10 - -
14. The route of administration of the test NP was stated. 10 - -
15. The placebo or comparison treatment and the test NP were 
matched in terms of taste, smell, appearance and dosing 
regimens.
10 - -
16. The success of blinding was evaluated. 10 - -BMC Complementary and Alternative Medicine 2009, 9:11 http://www.biomedcentral.com/1472-6882/9/11
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other items were grouped together because they were spe-
cific to the matching of the NP and placebo/comparator.
Phase 2. Establishment of important non-NP items
Identification of critical appraisal instruments for RCTs of 
conventional medications
The initial search of databases and hand searching of
investigators files, websites, textbooks, and reference lists
for critical appraisal instruments for RCTs of conventional
medications and NPs identified 4442 citations (Figure 2).
A review of the titles of the citations resulted in the exclu-
sion of 4032 citations. Review of the remaining 410
abstracts identified 229 potentially relevant articles, 200
of which were for instruments specifically for RCTs of con-
ventional medication. The remaining 29 potentially rele-
vant articles pertained to instruments for RCTs of NPs and
were systematically reviewed separately [2]. Upon further
examination, 99 of the 200 articles met the inclusion cri-
teria for instruments for RCTs of conventional medication
[4,6,9-105]. The 99 articles consisted of 87 instruments
for RCTs of conventional medications and 12 guidance
documents written to guide reporting of an RCT and/or
discussed the importance of quality assessment of RCTs of
conventional medicine.
Compilation of items from critical appraisal instruments for 
conventional medications
4 of the 99 instruments stated that they had been vali-
dated [6,28,63,104]. Therefore, all 17 general item catego-
ries contained in the validated instruments were
designated for inclusion in the new instrument (Table 2).
Four of the 17 items categories: sequence generation (for
randomization), blinding, participant flow and baseline
data were further supported for inclusion by empirical evi-
dence. [37,40,106-110]
The new instrument for the critical appraisal of RCTs of
NPs was assembled by combining the 17 general item cat-
egories identified as being important to assess with con-
ventional medications (Table 2) with the essential items
specific for the content of NPs determined in the Delphi
consensus process (Figure 1). In some cases, item state-
ments were further divided to provide clarity. For exam-
ple, the general item category of "blinding" was divided
into two items in the new assessment instrument: item #7.
(The study was blinded) and item #24 (The success of
blinding was evaluated). A section titled "reviewer's con-
clusion" was added to the end of the instrument to allow
the reviewer to reflect on their findings after the evalua-
tion of an article using the new instrument is complete.
This included 2 questions to help the user apply the
results to their practice. A User's Guide was developed to
facilitate the correct and consistent use of the instrument.
It included a section describing the purpose of the instru-
ment and definition of each item
Phase 3. Field test of new assessment instrument
Fourteen participants were enrolled in the RCT, pharma-
cists (n = 6), academics (n = 3) and pharmacy students (n
= 5). Thirteen of 14 participants completed the study; 6 in
the group that used the new assessment instrument first
and 7 in the group that used the comparator instrument
before using the new assessment instrument. The one
dropout was unable to complete the study within the
specified time frame due to unforeseen circumstances.
Responses, for each of the 3 articles, to each item in the
new assessment instrument were recorded and compared
between participants, regardless of the order in which the
instrument was used. There was general agreement among
participants as to the answers for most of the items in the
new assessment instrument, for all 3 articles. Items pro-
ducing the most discrepancy in answers were those deal-
ing with the description of the NP.
Statistical analysis of participants' responses for each item
in the new assessment instrument to the gold standard
responses of the investigators for each of the 3 papers
revealed that there was no significant difference in
answers, indicating strong criterion validity Statistical
analysis showed that the order in which the 2 instruments
were used had no significant effect on responses to any of
the items in the new assessment instrument.
The critical appraisal of the overall quality of each paper
produced similar results, regardless of which instrument
was used. That is, the paper that was judged to be of best
quality of the three papers analyzed using the comparator
instrument was also found by participants to be of the
best quality using the new instrument
Participants' responses to the "Reviewer's Conclusion"
section of the new assessment instrument were compared
to the gold standard responses of the investigators. Eight
of 13 participants (50% of those who used the new assess-
ment instrument first and 71% of those who used the new
assessment instrument second) felt that there was enough
detail provided in Paper A (not in Paper B or C) to allow
them to select a similar product, therefore agreeing with
the gold standard. The group using the new assessment
instrument second reported feeling much more comforta-
ble in finding a product to recommend.
Participants who used the published assessment instru-
ment first were fairly evenly split as to whether, after
reviewing the papers, they would recommend the treat-
ment to their patients. This was in contrast to those from
the group who used the published assessment instrument
after having used the new assessment instrument. They
were more likely to say that they would not recommend
the treatment.BMC Complementary and Alternative Medicine 2009, 9:11 http://www.biomedcentral.com/1472-6882/9/11
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Final list of items essential in describing the identity of an NP Figure 1
Final list of items essential in describing the identity of an NP.
The description of the NP included: 
(a) If the NP is (or was made from) a plant, microorganism or animal: 
I.  The genus and species 
II.  The part of the plant, microorganism or animal that was used 
II.  How the NP was prepared (extracted or processed) 
(b)  If the NP was composed of one or more chemical constituent(s), either derived 
from a plant, microorganism or animal or produced synthetically: 
I.  The complete name of the chemical constituent(s) 
(c)  If the NP was a commercially prepared product (regardless if it fits into category 
(a) or (b): 
I.  The brand name 
II. The  manufacturer 
III.  The lot or batch number(s) 
(d) The name(s) of the active or marker chemical(s) 
(e) The amount (weight or %) of the active or marker chemical(s) 
(f) A qualitative and quantitative analysis of active or marker chemical(s) 
(g) The dosage form 
(h) The daily dose 
The NP and placebo/comparison treatment were matched in terms of: 
(a) Taste, smell and / or appearance 
(b) Dosing regimen 
The success of blinding was evaluated BMC Complementary and Alternative Medicine 2009, 9:11 http://www.biomedcentral.com/1472-6882/9/11
Page 8 of 13
(page number not for citation purposes)
Results of search for critical appraisal instruments for RCTs of conventional medications Figure 2
Results of search for critical appraisal instruments for RCTs of conventional medications.
410 abstracts reviewed
200 articles reviewed
4032 citations excluded: 
not relevant 
181 abstracts excluded: 
not relevant 
Reasons 101 articles excluded:
Contained published tool 36 
Not specific for RCT 16 
Nonmedication therapy 18 
No instrument in paper 17 
Other 14
99 articles 
met criteria 
for inclusion 
56 checklists 
21 numeric 
scales 
12 guidance 
documents*
3 rating scales
87 instruments 
29 abstracts excluded:
instruments for RCTs of NPs 
7 combination 
scales and 
checklists
Database searches and 
hand searching 
4442 citations reviewed 
* Guidance Documents: Articles detailing how to report an RCT and/or discussing importance of 
quality assessment and providing suggested items of importance. BMC Complementary and Alternative Medicine 2009, 9:11 http://www.biomedcentral.com/1472-6882/9/11
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The new assessment instrument was favored by partici-
pants in 3 out of 4 questions that participants completed
as part of the Evaluation Form. Eleven of 13 found the
new instrument to be most helpful identifying strengths
and weaknesses of the studies, 8 of 13 felt that the new
instrument was best at helping to answer the clinical ques-
tion and 11 of 12 found the new instrument the most
helpful in selecting an NP comparable to one used in the
RCT. Participants were fairly evenly split as to which
instrument they found easier to use. Overall, 12 of 13 par-
ticipants preferred the new assessment instrument, stating
that they liked the detailed questions about the identity of
the NP. Feedback from the participant who preferred the
comparator assessment instrument reported liking the
numerical score that was generated by using the compara-
tor instrument as an indication of quality. The new assess-
ment instrument was favored over the published
assessment instrument by the group who used the new
instrument second, however, the participants who used
the new assessment instrument first were less clear as to
which instrument they preferred.
The new critical appraisal instrument was refined, based
on participants' feedback and is included as Additional
file 1. The final version of the User's Guide is presented in
Additional file 2.
Discussion
Development of instrument
The Delphi process is a well recognized technique used to
reach consensus among a group of experts [111]. Using
content experts in the Delphi process to establish a list of
essential NP items to include in the critical appraisal
instrument ensured content validity of the items [111-
113].
Results from Round 1 showed that participants, in gen-
eral, agreed with the inclusion of the majority of the items
in the new critical appraisal instrument. The depth and
breadth of expertise of participants was evident in sugges-
tions of additional items and changes in wording to
improve clarity. The most challenging issue raised by par-
ticipants in Round 1 was to identify the correct terminol-
ogy to use for the chemicals contained in the NP. Items in
the initial list asked for reports of RCTs to name "impor-
tant" chemicals, their amounts and state whether the NP
was analyzed for chemical content. Participants agreed
that these items were essential but reported that the term
"important chemicals" was vague or unclear. Assigning an
unambiguous term to these chemicals is complicated by
the fact that in some NPs, chemicals many have been
determined to be "pharmacologically active", while in
other NPs, in the active chemicals are unknown and so
product content is standardized to marker chemicals.
Round 2 was used to achieve consensus on rewording of
items and additional items as per suggestions from partic-
ipants. The list of items was also reorganized for ease of
use. Results of Round 2, coupled with investigators input,
resulted in the list of essential items presented in Figure 1,
which will become part of the new instrument for critical
appraisal of RCTs of NPs. While the list contained many
of the items found in other instruments, the Delphi con-
sensus process, using the expertise of 11 participants, pro-
vided a forum for ensuring all items were essential to
clearly define the NP being evaluated, were in language
Table 2: Support for inclusion of items in critical appraisal instruments for RCTs of conventional medicine.
General Item Categories Part of validated tool Empirical evidence
Participants yes
Interventions Yes
Objectives Yes
Outcomes (Methods) Yes
Sample size Yes
Sequence generation (Randomization) Yes Yes
Allocation concealment
(Randomization)
Yes
Blinding Yes Yes
Statistical flow Yes
Participant flow Yes Yes
Baseline data Yes Yes
Numbers analyzed Yes
Outcomes and estimation (Results) Yes
Ancillary analysis Yes
Adverse effects Yes
Interpretation Yes
Generalizability YesBMC Complementary and Alternative Medicine 2009, 9:11 http://www.biomedcentral.com/1472-6882/9/11
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that was clear and unambiguous to users with a variety of
backgrounds and were presented in a user friendly format.
Identification of non-NP items for the instrument was
achieved by examining the content of 99 published instru-
ments and guidance documents for the critical appraisal of
conventional medications. Initially it was proposed that
the items that appeared most frequently in the instruments
would be likely to be the ones of most importance. While
good in theory, there were two limitations with relying
exclusively on frequency as an indicator of importance.
Firstly, although there were 99 instruments and guidance
documents to examine, the actual number of unique
instruments was much smaller. This was a result of the fact
that some instruments were not truly new instruments but
were actually adaptations of earlier instruments. We felt
that it was important to include these adapted instruments
in our analysis as, the fact that researchers felt their initial
content was worthwhile to retain and modify suggested
their value. It was also important to identify what adapta-
tions had been made as there was the possibility of identi-
fying new items. The limitation of including these adapted
instruments in our analysis was that there was the potential
that some items could have been carried along into the
revised instruments, increasing the frequency score of the
item overall, but without the importance of the item being
adequately assessed in the revision of the instrument. The
second limitation of relying on frequency as the only indi-
cator of an item's importance is that as understanding of
critical appraisal develops, new items determined to be
essential have been and will be added to new instruments.
Because the items are new, their overall frequency of inclu-
sion in instruments will be low and, by our criteria, would
not have been included in our new instrument. It was for
these two reasons that frequency of inclusion in an instru-
ment was removed from the list of criteria for including
non-NP items in our new instrument.
While frequency of inclusion of items in instruments is an
indicator of their perceived importance, to overcome some
of the inherent limitations described above, it was decided
to include items that had empirical evidence to support
their inclusion or were contained in instruments that said
they had been validated. Only 4 of the 99 instruments were
described by their authors as having been validated
[6,28,63,104]. Interestingly, these 4 instruments were also
designed using empirical methods of development includ-
ing revisions based on inter-rater agreement or comments
on content validity [6,63], Delphi consensus [28], and a
modified Nominal Group Technique [104].
Evaluation of instrument
The new assessment instrument, developed using a Del-
phi process and defined criteria to ensure that items had
strong support for inclusion, was tested by anticipated
users of a critical appraisal instrument. This included
pharmacists, pharmacy educators and pharmacy students,
each with a range of experience in critical appraisal and
knowledge of issues important to NPs. An important part
of the evaluation was to have participants be able to com-
pare the new instrument to a published instrument that
was designed specifically for use with NPs and that all
identifiers from articles and instruments be removed to
reduce the risk of bias.
Items in the new assessment instrument producing the
most discrepancy in answers dealt with the identity of the
NP. The range in answers was likely a result of lack of clar-
ity in the items and so each of the NP items was examined
and modified if required, to reduce ambiguity.
Randomizing the order in which participants used the 2
assessment instruments allowed us to probe whether the
order affected their responses to items in the new assess-
ment instrument. The fact that the order of use had no sta-
tistically significant affect on answers to items on the new
assessment instrument allowed us to pool answers from
both groups when assessing criterion validity by compar-
ing participants' answers to the gold standard, thereby giv-
ing a larger sample size.
Strengths and Limitations
The strength of the new assessment instrument described
in this paper is the method used for its development.
Identification and assessment of items for inclusion in the
new assessment was based on clearly defined criteria. The
use of experts in the Delphi process to guide the develop-
ment of the list of items essential to include for NPs was
clearly a strength, as was the evaluation of the instrument
to validate criterion. This is an advantage over all pub-
lished instruments for NPs that we identified.
A potential limitation of the instrument is that the initial
list of both NP and non-NP items was dependent on the
content of assessment instruments identified in the litera-
ture. The literature search was completed in June 2006
and it is possible, despite the fact that the investigators
routinely monitor the newly published literature in this
area, that newer instruments were not identified. It is also
possible, due to the complexity of the nature of the data-
base searching on this topic that not all relevant instru-
ments were identified. Search results revealed that there
was inconsistency in the key words used to index articles
containing instruments and guidance documents. Both
the time lag since the initial search and the difficulty in
searching the databases could have resulted in some
instruments not being identified thereby affecting the list
of items. Additionally, because the search of the literature
was limited to articles published in English, this may have
also resulted in an incomplete identification of articles.BMC Complementary and Alternative Medicine 2009, 9:11 http://www.biomedcentral.com/1472-6882/9/11
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The number of items contained in the new instrument may
be viewed as both a strength and a limitation. The number
of items attests to its attempt to be complete in its assess-
ment of the RCTs, however, some potential users may find
the time needed to address each item prohibitive.
Conclusion
A new instrument for the critical appraisal of RCTs of NPs
was developed and evaluated. The NP section of the
instrument was developed through consensus of a group
of experts in NP and critical appraisal, ensuring content
validity. The non-NP section of the instrument was con-
structed using items that were contained in instruments
that had been validated or had empirical evidence to sup-
port their inclusion. The new assessment instrument was
tested by a group of potential users who determined it to
be helpful in evaluating RCTs to aid in answering a clini-
cal question, as compared to a published comparator
instrument. The instrument is distinct from other availa-
ble assessment instruments for RCTs of NPs in its system-
atic development and validation. It has the additional
advantage that its use is not restricted to herbs, rather it
can be used with for all "single entity" NPs, such as glu-
cosamine for example. The instrument is ready to be used
by pharmacy students, health care practitioners and aca-
demics and will continue to be refined as required.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
TJ and AMW designed all studies, interpreted data and
drafted manuscript. MMM conducted Delphi consensus
rounds and the instrument evaluation trial. LL was
responsible for database searching, relevance assessment
and data extraction and some interpretation. All authors
read and approved manuscript.
Additional material
Acknowledgements
Funding for the project and studentship support was provided by the Dal-
housie Pharmacy Endowment Fund and a Dalhousie University Faculty of 
Health Professions Research Development Grant. Thanks are extended to 
Dr. David Gardner and Dr Richard Braha for helping with early project 
development and to Angela Hazel and Stephanie Keith for their contribu-
tions to the project. The statistical analysis was provided by Vaneeta Kaur 
Grover.
References
1. Chan E: Quality of efficacy research in Complementary and
Alternative Medicine. Editorial.  JAMA 2008,
299(22):2685-2686.
2. Whelan AM, Jurgens TM, Lord L: Evaluating the quality of rand-
omized controlled trials that examine the efficacy of natural
health products: a systematic review of critical appraisal
instruments.  Evid Based Complement Alternat Med 2008.
3. Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C,
CONSORT Group: Reporting randomized, controlled trials of
herbal interventions: an elaborated CONSORT statement.
Ann Intern Med 2006, 144(5):364-367.
4. Verhagen AP, de Vet HC, de Bie RA, Kessels AG, Boers M, Bouter
LM, Knipschild PG: The Delphi list: a criteria list for quality
assessment of randomized clinical trials for conducting sys-
tematic reviews developed by Delphi consensus.  J Clin Epide-
miol 1998, 51(12):1235-1241.
5. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D,
Gotzsche PC, Lang T, CONSORT GROUP (Consolidated Standards
of Reporting Trials): The revised CONSORT statement for
reporting randomized trials: explanation and elaboration.
Ann Intern Med 2001, 134(8):663-694.
6. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan
DJ, McQuay HJ: Assessing the quality of reports of randomized
clinical trials: is blinding necessary?  Control Clin Trials 1996,
17(1):1-12.
7. Low Dog T: Clinical Trial Reviewer's Guidance and Checklist.
In The Handbook of Clinically Tested Herbal Remedies Volume 1. Edited
by: Barrett M. Birmingham, New York: The Haworth Press, Inc;
2004:141-148. 
8. Gardner DM: Evidence-based decisions about herbal products
for treating mental disorders.  J Psychiatry Neurosci 2002,
27(5):324-333.
9. Turlik MA, Kushner D, Stock D: Assessing the validity of pub-
lished randomized controlled trials in podiatric medical jour-
nals.  J Am Podiatr Med Assoc 2003, 93(5):392-398.
10. Vamvakas EC: Rationale, objectives, and interpretation of ran-
domized controlled trials.  J Clin Apher 1997, 12(3):130-139.
11. Heijden GJ van der, Windt DA van der, Kleijnen J, Koes BW, Bouter
LM: Steroid injections for shoulder disorders: a systematic
review of randomized clinical trials.  Br J Gen Pract 1996,
46(406):309-316.
12. van Tulder MW, Koes BW, Bouter LM: Conservative treatment
of acute and chronic nonspecific low back pain. A systematic
review of randomized controlled trials of the most common
interventions.  Spine 1997, 22(18):2128-2156.
13. Weintraub M: How to Critically Assess Clinical Drug Trials.
Drug Ther 1982:131-148.
14. Working Group on Recommendations for Reporting of Clinical Trials
in the Biomedical Literature: Call for comments on a proposal to
improve reporting of clinical trials in the biomedical litera-
ture.  Ann Intern Med 1994, 121(11):894-895.
15. Zelen M: Guidelines for publishing papers on cancer clinical
trials: responsibilities of editors and authors.  J Clin Oncol 1983,
1(2):164-169.
16. Nurmohamed MT, Rosendaal FR, Buller HR, Dekker E, Hommes
DW, Vandenbroucke JP, Briet E: Low-molecular-weight heparin
versus standard heparin in general and orthopaedic surgery:
a meta-analysis.  Lancet 1992, 340(8812):152-156.
17. Onghena P, Van Houdenhove B: Antidepressant-induced analge-
sia in chronic non-malignant pain: a meta-analysis of 39 pla-
cebo-controlled studies.  Pain 1992, 49(2):205-219.
18. Pater JL, Weir L: Reporting the results of randomized trials of
empiric antibiotics in febrile neutropenic patients – a critical
survey.  J Clin Oncol 1986, 4(3):346-352.
Additional file 1
Appendix A.
Appendix A. Final version of new assessment instrument developed for the 
critical appraisal of RCTs of NPs.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-
6882-9-11-S1.doc]
Additional file 2
Appendix B.
Appendix B. User's Guide for Dalhousie Assessment Instrument for Crit-
ical Appraisal of Randomized Controlled Trials (RCTs) of Natural Prod-
ucts (NPs).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-
6882-9-11-S2.doc]BMC Complementary and Alternative Medicine 2009, 9:11 http://www.biomedcentral.com/1472-6882/9/11
Page 12 of 13
(page number not for citation purposes)
19. Pua HL, Lerman J, Crawford MW, Wright JG: An evaluation of the
quality of clinical trials in anesthesia.  Anesthesiology 2001,
95(5):1068-1073.
20. Reisch JS, Tyson JE, Mize SG: Aid to the evaluation of therapeu-
tic studies.  Pediatrics 1989, 84(5):815-827.
21. Rochon PA, Gurwitz JH, Cheung CM, Hayes JA, Chalmers TC: Eval-
uating the quality of articles published in journal supple-
ments compared with the quality of those published in the
parent journal.  JAMA 1994, 272(2):108-113.
22. Rothwell PM: External validity of randomised controlled trials:
"to whom do the results of this trial apply?".  Lancet 2005,
365(9453):82-93.
23. Sackett DL: How to read clinical journals: V: To distinguish
useful from useless or even harmful therapy.  Can Med Assoc J
1981, 124(9):1156-1162.
24. Schulz KF, Chalmers I, Hayes JA, Altman DG: Empirical evidence
of bias. Dimensions of methodological quality associated
with estimates of treatment effects in controlled trials.  JAMA
1995, 273(5):408-412.
25. Scottish Intercollegiate Guidelines Network   [ h t t p : / /
www.sign.ac.uk/methodology/checklists.html]
26. Seals DR, Tanaka H: Manuscript peer review: a helpful checklist
for students and novice referees.  Adv Physiol Educ 2000,
23(1):52-58.
27. Simon R, Wittes RE: Methodologic guidelines for reports of
clinical trials.  Cancer Treat Rep 1985, 69(1):1-3.
28. Sindhu F, Carpenter L, Seers K: Development of a tool to rate
the quality assessment of randomized controlled trials using
a Delphi technique.  J Adv Nurs 1997, 25(6):1262-1268.
29. Stoddard GJ, Ring WH: How to evaluate study methodology in
published clinical research.  J Intraven Nurs 1993, 16(2):110-117.
30. Strippoli GF, Craig JC, Schena FP: The number, quality, and cov-
erage of randomized controlled trials in nephrology.  J Am Soc
Nephrol 2004, 15(2):411-419.
31. The Asilomar Working Group on Recommendations for Reporting of
Clinical Trials in the Biomedical Literature: Checklist of informa-
tion for inclusion in reports of clinical trials.  Ann Intern Med
1996, 124(8):741-743.
32. The Standards of Reporting Trials Group: A proposal for struc-
tured reporting of randomized controlled trials.  JAMA 1994,
272(24):1926-1931.
33. Harrison JE: Clinical trials in orthodontics II: assessment of the
quality of reporting of clinical trials published in three ortho-
dontic journals between 1989 and 1998.  J Orthod 2003,
30(4):309-15. discussion 297–8.
34. What is . . . ? series   [http://www.whatisseries.co.uk/whatis/]
35. Huwiler-Muntener K, Juni P, Junker C, Egger M: Quality of report-
ing of randomized trials as a measure of methodologic qual-
ity.  JAMA 2002, 287(21):2801-2804.
36. Imperiale TF, McCullough AJ: Do corticosteroids reduce mortal-
ity from alcoholic hepatitis? A meta-analysis of the rand-
omized trials.  Ann Intern Med 1990, 113(4):299-307.
37. Juni P, Altman DG, Egger M: Systematic reviews in health care:
Assessing the quality of controlled clinical trials.  BMJ 2001,
323(7303):42-46.
38. Karassa FB, Tatsioni A, Ioannidis JP: Design, quality, and bias in
randomized controlled trials of systemic lupus erythemato-
sus.  J Rheumatol 2003, 30(5):979-984.
39. Khan KS, Daya S, Jadad A: The importance of quality of primary
studies in producing unbiased systematic reviews.  Arch Intern
Med 1996, 156(6):661-666.
40. Kjaergard LL, Frederiksen SL, Gluud C: Validity of randomized
clinical trials in gastroenterology from 1964–2000.  Gastroen-
terology 2002, 122(4):1157-1160.
41. Kjaergard LL, Nikolova D, Gluud C: Randomized clinical trials in
hepatology: predictors of quality.  Hepatology 1999,
30(5):1134-1138.
42. Levine J: Trial Assessment Procedure Scale.  In Guide to Clinical
Trials Edited by: Spilker B. New York: Raven Press, Ltd; 1991:780-786. 
43. Liberati A, Himel HN, Chalmers TC: A quality assessment of ran-
domized control trials of primary treatment of breast can-
cer.  J Clin Oncol 1986, 4(6):942-951.
44. Liddle J, Williamson M, Irwig L: Method for Evaluating Research
Guideline Evidence (MERGE).  Sydney: NSW Health Depart-
ment; 1996. 
45. Lionel ND, Herxheimer A: Assessing reports of therapeutic tri-
als.  Br Med J 1970, 3(723):637-640.
46. Lohr KN, Carey TS: Assessing "best evidence": issues in grad-
ing the quality of studies for systematic reviews.  Jt Comm J
Qual Improv 1999, 25(9):470-479.
47. Lopex LR: What are the essential factors in a critique of a
research study for determination of quality and applicability?
Fla Nurse 1987, 35(6):25.
48. Mahon WA, Daniel EE: A method for the assessment of reports
of drug trials.  Can Med Assoc J 1964, 90:565-569.
49. Makela M, Witt K: How to read a paper: critical appraisal of
studies for application in healthcare.  Singapore Med J 2005,
46(3):108-14. quiz 115.
50. Meade MO, Richardson WS: Selecting and appraising studies for
a systematic review.  Ann Intern Med 1997, 127(7):531-537.
51. Meinert CL: Questions and factors to consider when reading a
report from a clinical trial.  In Clinical Trials: Design, Conduct, and
Analysis Edited by: Meinert CL. New York: Oxford University Press;
1986:272-276. 
52. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P,
Klassen TP: Does quality of reports of randomised trials affect
estimates of intervention efficacy reported in meta-analy-
ses?  Lancet 1998, 352(9128):609-613.
53. Moher D, Schulz KF, Altman DG, CONSORT GROUP (Consolidated
Standards of Reporting Trials): The CONSORT statement:
revised recommendations for improving the quality of
reports of parallel-group randomized trials.  Ann Intern Med
2001, 134(8):657-662.
54. Mosteller F, Gilbert JP, McPeek B: Reporting standards and
research strategies for controlled trials. Agenda for the edi-
tor.  Control Clin Trials 1980, 1:37-58.
55. NHMRC (National Health and Medical Research Council): How to
review the evidence: systematic identification and review of the scientific lit-
erature Canberra: NHMRC; 2000. 
56. Public Health Resource Unit   [http://www.phru.nhs.uk/
Doc_Links/rct%20appraisal20%tool.pdf]
57. DerSimonian R, Charette LJ, McPeek B, Mosteller F: Reporting on
methods in clinical trials.  N Engl J Med 1982, 306(22):1332-1337.
58. Detsky AS, Naylor CD, O'Rourke K, McGeer AJ, L'Abbe KA: Incor-
porating variations in the quality of individual randomized
trials into meta-analysis.  J Clin Epidemiol 1992, 45(3):255-265.
59. Devereaux PJ, Manns BJ, Ghali WA, Quan H, Guyatt GH: The
reporting of methodological factors in randomized control-
led trials and the association with a journal policy to pro-
mote adherence to the Consolidated Standards of Reporting
Trials (CONSORT) checklist.  Control Clin Trials 2002,
23(4):380-388.
60. Dixon JS, Smith A, Evans SJ: Reporting clinical trials.  Br J Rheumatol
1983, 22(3 Suppl):74-78.
61. Djulbegovic B, Adams JR, Lyman GH, Lacevic M, Hozo I, Greenwich
M, Bennett CL: Evaluation and appraisal of randomized con-
trolled trials in myeloma.  Ann Oncol 2001, 12(11):1611-1617.
62. Doig GS: Interpreting and using clinical trials.  Crit Care Clin
1998, 14(3):513-524.
63. Downs SH, Black N: The feasibility of creating a checklist for
the assessment of the methodological quality both of ran-
domised and non-randomised studies of health care inter-
ventions.  J Epidemiol Community Health 1998, 52(6):377-384.
64. Ellenberg JH: Clinical trials.  Neurol Clin 1990, 8(1):15-30.
65. Evans M, Pollock AV: A score system for evaluating random
control clinical trials of prophylaxis of abdominal surgical
wound infection.  Br J Surg 1985, 72(4):256-260.
66. Evans M, Pollock AV: Trials on trial. A review of trials of antibi-
otic prophylaxis.  Arch Surg 1984, 119(1):109-113.
67. The Focus Project.  www.focusproject.org.uk . The above URL is no
longer active, for further information please contact the correspond-
ing author.
68. Fowkes FG, Fulton PM: Critical appraisal of published research:
introductory guidelines.  BMJ 1991, 302(6785):1136-1140.
69. Gardner MJ, Machin D, Campbell MJ: Use of check lists in assess-
ing the statistical content of medical studies.  Br Med J (Clin Res
Ed) 1986, 292(6523):810-812.
70. Gifford RH, Feinstein AR: A critique of methodology in studies
of anticoagulant therapy for acute myocardial infarction.  N
Engl J Med 1969, 280(7):351-357.BMC Complementary and Alternative Medicine 2009, 9:11 http://www.biomedcentral.com/1472-6882/9/11
Page 13 of 13
(page number not for citation purposes)
71. Gluud C, Nikolova D: Quality assessment of reports on clinical
trials in the Journal of Hepatology.  J Hepatol 1998,
29(2):321-327.
72. Gotzsche PC: Methodology and overt and hidden bias in
reports of 196 double-blind trials of nonsteroidal antiinflam-
matory drugs in rheumatoid arthritis.  Control Clin Trials 1989,
10(1):31-56.
73. Grant A: Reporting controlled trials.  Br J Obstet Gynaecol 1989,
96(4):397-400.
74. Grimes DA, Schulz KF: Methodology citations and the quality of
randomized controlled trials in obstetrics and gynecology.
Am J Obstet Gynecol 1996, 174(4):1312-1315.
75. Gross R, Keller DR: Appraising the evidence.  WMJ 1999,
98(2):44-48.
76. Gupta AK, Ryder JE, Bluhm R, Johnson A, Summerbell RC: Ony-
chomycosis: quality of studies.  J Cutan Med Surg 2003,
7(4):312-316.
77. Guyatt GH, Sackett DL, Cook DJ: Users' guides to the medical
literature. II. How to use an article about therapy or preven-
tion. B. What were the results and will they help me in caring
for my patients? Evidence-Based Medicine Working Group.
JAMA 1994, 271(1):59-63.
78. Guyatt GH, Sackett DL, Cook DJ: Users' guides to the medical
literature. II. How to use an article about therapy or preven-
tion. A. Are the results of the study valid? Evidence-Based
Medicine Working Group.  JAMA 1993, 270(21):2598-2601.
79. Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM,
Atkins D, Methods Work Group, Third US Preventive Services Task
Force: Current methods of the US Preventive Services Task
Force: a review of the process.  Am J Prev Med 2001, 20(3
Suppl):21-35.
80. Essential Evidence Plus   [http://www.infopoems.com/product/
methods_validity.cfm#]
81. Canadian Pharmacist's Letter   [http://www.pharmacistslet
ter.com]
82. University of Glasgow   [http://www.gla.ac.uk/media/
media_64037_en.pdf]
83. Faculty of Medicine and Dentistry, University of Alberta
[http://www.ebm.med.ualberta.ca/therapy.pdf]
84. Centre for Evidence Based Medicine   [http://www.cebm.net/
index.aspx?o=1157]
85. Ah-See KW, Molony NC: A qualitative assessment of rand-
omized controlled trials in otolaryngology.  J Laryngol Otol 1998,
112(5):460-463.
86. Ajetunmobi O: Critical appraisal of randomized clinical trials.
In Making Sense of Critical Appraisal Edited by: Ajetunmobi O. London:
Arnold; 2002:122-145. 
87. Antczak AA, Tang J, Chalmers TC: Quality assessment of rand-
omized control trials in dental research. I. Methods.  J Perio-
dontal Res 1986, 21(4):305-314.
88. Avis M: Reading research critically. II. An introduction to
appraisal: assessing the evidence.  J Clin Nurs 1994, 3(5):271-277.
89. Balk EM, Bonis PA, Moskowitz H, Schmid CH, Ioannidis JP, Wang C,
Lau J: Correlation of quality measures with estimates of
treatment effect in meta-analyses of randomized controlled
trials.  JAMA 2002, 287(22):2973-2982.
90. Bath FJ, Owen VE, Bath PM: Quality of full and final publications
reporting acute stroke trials: a systematic review.  Stroke
1998, 29(10):2203-2210.
91. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R,
Rennie D, Schulz KF, Simel D, Stroup DF: Improving the quality of
reporting of randomized controlled trials. The CONSORT
statement.  JAMA 1996, 276(8):637-639.
92. Bigby M, Gadenne AS: Understanding and evaluating clinical tri-
als.  J Am Acad Dermatol 1996, 34(4):555-90. quiz 591–3.
93. Bigby M, Stern RS, Bigby JA: An evaluation of method reporting
and use in clinical trials in dermatology.  Arch Dermatol 1985,
121(11):1394-1399.
94. Bland JM, Jones DR, Bennett S, Cook DG, Haines AP, MacFarlane AJ:
Is the clinical trial evidence about new drugs statistically ade-
quate?  Br J Clin Pharmacol 1985, 19(2):155-160.
95. Brown CG, Kelen GD, Moser M, Moeschberger ML, Rund DA:
Methodology reporting in three acute care journals: replica-
tion and reliability.  Ann Emerg Med 1985, 14(10):986-991.
96. Brown CG, Moser M, Moeschberger M, Kelen GD: Controlled clin-
ical trials in emergency medicine.  Am J Emerg Med 1985,
3(1):67-73.
97. Byers JF, Beaudin CL: Critical appraisal tools facilitate the work
of the quality professional.  J Healthc Qual 2001, 23(5):35-8. 40–3.
98. Carneiro AV: Critical appraisal of clinical studies: practical
tables.  Rev Port Cardiol 2005, 24(4):607-614.
99. cebmh   [http://cebmh.warne.ox.ac.uk/cebmh/downloads/
education_resources/overview.pdf]
100. Chalmers I, Adams M, Dickersin K, Hetherington J, Tarnow-Mordi
W, Meinert C, Tonascia S, Chalmers TC: A cohort study of sum-
mary reports of controlled trials.  JAMA 1990,
263(10):1401-1405.
101. Chalmers TC, Smith H Jr, Blackburn B, Silverman B, Schroeder B,
Reitman D, Ambroz A: A method for assessing the quality of a
randomized control trial.  Control Clin Trials 1981, 2(1):31-49.
102. Chan AW, Altman DG: Epidemiology and reporting of ran-
domised trials published in PubMed journals.  Lancet 2005,
365(9465):1159-1162.
103. Chan KB, Man-Son-Hing M, Molnar FJ, Laupacis A: How well is the
clinical importance of study results reported? An assessment
of randomized controlled trials.  CMAJ 2001, 165(9):1197-1202.
104. Cho MK, Bero LA: Instruments for assessing the quality of drug
studies published in the medical literature.  JAMA 1994,
272(2):101-104.
105. Colditz GA, Miller JN, Mosteller F: How study design affects out-
comes in comparisons of therapy. I: Medical.  Stat Med 1989,
8(4):441-454.
106. Schulz KF: Subverting randomization in controlled trials.  JAMA
1995, 274(18):1456-1458.
107. Noseworthy JH, Ebers GC, Vandervoort MK, Farquhar RE, Yetisir E,
Roberts R: The impact of blinding on the results of a rand-
omized, placebo-controlled multiple sclerosis clinical trial.
Neurology 1994, 44:16-20.
108. Egger M, Juni P, Bartlett C: Value of flow diagrams in reports of
randomized controlled trials.  JAMA 2001, 285:1996-1999.
109. May GS, Chir B, Demets DL, Friedman LM, Furberg C, Passamani E:
The randomized clinical trial: bias in analysis.  Circulation 1981,
64:669-673.
110. Sackett DL, Gent M: Controversy in counting and attributing
events in clinical trials.  New Eng J Med 1979, 301:1410-1412.
111. Hasson F, Keeney S, McKenna H: Research guidelines for the
Delphi survey technique.  J Adv Nurs 2000, 32(4):1008-15.
112. Frost MH, Reeve BB, Liepa AM, Stauffer JW, Hays RD, the Mayo/FDA
Patient-Reported Outcomes Consensus Meeting Group: What is
sufficient evidence for the reliability and validity of patient-
reported outcome measures?  Value Health 2007, 10(Suppl
2):S94-S105.
113. Burns KEA, Duffett M, Kho ME, Meade MO, Adhikari NKJ, Sinuff T,
Cook DJ, Abenhaim L, Sinuff T, Cook DJ: A. guide for the design
and conduct of self-administered surveys of clinicians.  CMAJ
2008, 179(3):245-252.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1472-6882/9/11/prepub